Literature DB >> 8686739

Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.

D Tabernero1, J F San Miguel, M Garcia-Sanz, L Nájera, M García-Isidoro, J A Peréz-Simon, M Gonzalez, J Wiegant, A K Raap, A Orfão.   

Abstract

The presence of complex karotypes with frequent numerical and structural abnormalities has been reported in 20 to 50% of multiple myeloma (MM) patients. This variability is mainly due to the difficulty of conventional cytogenetics to obtain tumor metaphases representative of all possible neoplastic clones in MM. To gain insight into the real incidence of numerical chromosome changes in MM we have studied by fluorescence in situ hybridization technique 15 different human chromosomes, 1, 3, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, X, and Y, in a series of 52 MM patients. In all cases, the DNA index assessed by a propidium iodide/CD38 double-staining technique with flow cytometry was simultaneously investigated for correlation, with fluorescence in situ hybridization results. Additional aims of this study were 1) to analyze whether the abnormalities detected were common to all plasma cells or were present in only a subpopulation of tumor cells, 2) to explore changes caused by disease progression, and 3) to establish possible associations among the altered chromosomes. Although the overall incidence of numerical abnormalities was 67%, this frequency increased to 80% in the 41 cases in which 7 or more chromosomes were analyzed. Trisomies were significantly more common than monosomies (84% versus 16%). Chromosomes 9 and 15 were the most frequently altered (52% and 48% of cases, respectively), with all of their abnormalities corresponding to trisomies. The most frequent losses involved chromosomes 13 (26%) and X in females (32%). Other common numerical changes corresponded to chromosomes 1 (39%), 11 (37%), 6 (32%), 3 (31%), 18 (29%), 7 (28%), and 17 (22%). By contrast, chromosomes 8(13%), 10(8%), and 12(3%) were rarely altered. DNA aneuploidy by flow cytometry was detected in 67% of patients, and a high degree of correlation was observed between the DNA index obtained by flow cytometry and the chromosome index derived from fluorescence in situ hybridization studies, calculated according to two mathematical formulas (coefficient of correlation of 0.82 and 0.91 when at least 7 or 12 chromosomes were considered, respectively). The frequency of numeric chromosome aberrations was higher in those patients with progressive disease and, interestingly, trisomy of chromosome 8 was exclusively detected in this latter group of patients. Our study shows that, with the exception of chromosome 8, a possible marker of clonal evolution, the numeric chromosome changes are present in nearly all malignant plasma cells (r > 0.84). Finally, frequent associations between chromosomal aberrations were observed (ie, chromosomes 6, 7, 9, and 17; 7 and 15; and 11 and 17). By excluding them, it was found that two triple combinations of chromosome-specific probes, chromosomes 1 and 9 together with either chromosome 13 or 15, could be a useful marker for detection of residual disease, as it permits the identification of most MM patients displaying numerical changes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686739      PMCID: PMC1865243     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Plasma cell karyotype in multiple myeloma.

Authors:  J Gould; R Alexanian; A Goodacre; S Pathak; B Hecht; B Barlogie
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

2.  Prognostic significance of single chromosome abnormalities in preleukemic states.

Authors:  P C Nowell; E C Besa
Journal:  Cancer Genet Cytogenet       Date:  1989-10-01

3.  Sequence relationships of three human satellite DNAs.

Authors:  J Prosser; M Frommer; C Paul; P C Vincent
Journal:  J Mol Biol       Date:  1986-01-20       Impact factor: 5.469

4.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.

Authors:  G W Dewald; R A Kyle; G A Hicks; P R Greipp
Journal:  Blood       Date:  1985-08       Impact factor: 22.113

Review 5.  Chromosome 1 aberrations in cancer.

Authors:  N B Atkin
Journal:  Cancer Genet Cytogenet       Date:  1986-04-15

6.  Ploidy and proliferative characteristics in monoclonal gammopathies.

Authors:  J Latreille; B Barlogie; D Johnston; B Drewinko; R Alexanian
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

7.  Abnormalities of chromosome 1 in relation to human malignant diseases.

Authors:  E Oláh; E Balogh; I Kovács; A Kiss
Journal:  Cancer Genet Cytogenet       Date:  1989-12

8.  Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.

Authors:  J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jimenez; L Guerras; M Romero; F Casanova
Journal:  Br J Haematol       Date:  1991-02       Impact factor: 6.998

9.  Cytogenetic study in multiple myeloma.

Authors:  A Ferti; A Panani; G Arapakis; S Raptis
Journal:  Cancer Genet Cytogenet       Date:  1984-07

Review 10.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.

Authors:  J L Laï; M Zandecki; J Y Mary; F Bernardi; V Izydorczyk; M Flactif; P Morel; J P Jouet; F Bauters; T Facon
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

View more
  11 in total

1.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

4.  CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities.

Authors:  R Avva; R L Vanhemert; B Barlogie; N Munshi; E J Angtuaco
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

5.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Authors:  G Pruneri; S Fabris; L Baldini; N Carboni; S Zagano; M A Colombi; G Ciceri; L Lombardi; M Rocchi; R Buffa; A T Maiolo; A Neri
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?

Authors:  José María Sayagués; María Dolores Tabernero; Angel Maíllo; Ana Espinosa; Ana Rasillo; Pedro Díaz; Juana Ciudad; Antonio López; Marta Merino; Jesús María Gonçalves; Angel Santos-Briz; Francisco Morales; Alberto Orfao
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

7.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

8.  Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.

Authors:  Naohiro Sekiguchi; Kaori Ootsubo; Miyuki Wagatsuma; Kiyoe Midorikawa; Akihisa Nagata; Satoshi Noto; Kazuaki Yamada; Naoki Takezako
Journal:  Int J Hematol       Date:  2014-02-05       Impact factor: 2.490

Review 9.  Molecular biology of myeloma.

Authors:  N C Gutiérrez; R García-Sanz; J F San Miguel
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

10.  Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients.

Authors:  M H Ng; A Kan; Y F Chung; I H Wong; K W Lo; N W Wickham; K I Lei; J C Lee
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.